{"id":3543,"date":"2020-06-24T15:52:38","date_gmt":"2020-06-24T19:52:38","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/"},"modified":"2026-11-04T04:35:11","modified_gmt":"2026-11-04T03:35:11","slug":"presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/","title":{"rendered":"Pr\u00e9sentation par des Leaders d&rsquo;Opinions du LUMEVOQ\u00ae pour le traitement de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL)"},"content":{"rendered":"\nLa conf\u00e9rence comprendra les pr\u00e9sentations de deux Leaders d&rsquo;Opinions Nancy Newman, MD (Emory Eye Center) et Sean Donahue, MD, PhD (Vanderbilt Children&rsquo;s Hospital) qui discuteront des traitements actuels et des besoins m\u00e9dicaux non satisfaits dans la neuropathie optique h\u00e9r\u00e9ditaire de Leber ( LHON). Drs. Newman et Donahue seront disponibles pour r\u00e9pondre aux questions \u00e0 la fin de la conf\u00e9rence.\n\nDe plus, l&rsquo;\u00e9quipe de direction de GenSight fera le point sur la soci\u00e9t\u00e9 et discutera des r\u00e9sultats des essais de phase III REVERSE et RESCUE pour LUMEVOQ\u00ae (GS010). RESCUE et REVERSE sont deux \u00e9tudes de phase III randomis\u00e9es, en double masqu\u00e9, contr\u00f4l\u00e9es par injection simul\u00e9e (sham), con\u00e7ues pour \u00e9valuer l\u2019efficacit\u00e9 d\u2019une injection intravitr\u00e9enne unique de GS010 (rAAV2\/2-ND4) chez des sujets atteints de la NOHL induite par la mutation G11778A du g\u00e8ne mitochondrial ND4. Le LUMEVOQ\u00ae (GS010) devrait \u00eatre soumis \u00e0 l&rsquo;approbation europ\u00e9enne en septembre 2020.\n\nLUMEVOQ\u00ae (GS010) cible la neuropathie optique h\u00e9r\u00e9ditaire Leber (LHON) en s&rsquo;appuyant sur une plateforme technologique propri\u00e9taire de s\u00e9quence de ciblage mitochondriale (MTS) d\u00e9velopp\u00e9e \u00e0 partir de recherches men\u00e9es \u00e0 l&rsquo;Institut de la Vision \u00e0 Paris. La technologie permet \u00e0 GS010 d&rsquo;utiliser un vecteur AAV (Adeno-Associated Virus) con\u00e7u pour corriger les d\u00e9fauts \u00e0 l&rsquo;int\u00e9rieur des mitochondries.\n<h3><strong>information pour rejoindre la conference\u00a0<\/strong><\/h3>\n<ul>\n \t<li>Domestic: 1-877-705-6003<\/li>\n \t<li>International: 1-201-493-6725<\/li>\n \t<li>Conference ID: 13705257<\/li>\n<\/ul>\nRejoindre la conf\u00e9rence : cliquer <a href=\"https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1332930&amp;tp_key=cef357cbf4\" target=\"_blank\" rel=\"noopener\"><strong>ici\u00a0<\/strong><\/a>\n\nPour ceux qui ne peuvent pas \u00e9couter \u00e0 ce moment, la pr\u00e9sentation sera disponible en ligne <a href=\"https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1332930&amp;tp_key=cef357cbf4\" target=\"_blank\" rel=\"noopener\">ici<\/a>.\n<h3><strong>Information Q&amp;A\u00a0<\/strong><\/h3>\nSi vous souhaitez poser une question pendant le Q&amp;A en direct, veuillez soumettre votre demande par e-mail : <a href=\"mailto:questions@lifesciadvisors.com\">Email Q&amp;A<\/a>\n<h3><strong>Biographies des leaders d&rsquo;opinions<\/strong><\/h3>\n<ul>\n \t<li><strong>Nancy Newman, MD<\/strong><\/li>\n<\/ul>\nNancy J. Newman, MD is the LeoDelle Jolley Professor of Ophthalmology, Professor of Ophthalmology and Neurology and Instructor in Neurological Surgery at the Emory University School of Medicine, where she serves as the Director of Neuro-Ophthalmology.\u00a0She attended Princeton University, the University of London on a Marshall Scholarship, and Harvard Medical School.\u00a0She trained in Internal Medicine and Neurology at the Massachusetts General Hospital where she was Chief Resident in Neurology, and in Neuro-Ophthalmology at the Massachusetts Eye and Ear Infirmary.\u00a0She is a Fellow of the American Academy of Neurology, the American Neurological Association, and the North American Neuro-Ophthalmology Society.\n\nShe was President of the North American Neuro-Ophthalmology Society from 2014 to 2016, Chair of the Board of Directors from 2016 to 2018, and is now Senior Vice President for Education. She has served on the Editorial Boards of the American Journal of Ophthalmology, Seminars in Neurology, Journal of the Neurological Sciences and the Journal of Neuro-Ophthalmology.\u00a0She has over 500 publications, including scientific articles, book chapters and books, including the primary textbook in Neuro-Ophthalmology,\u00a0<em>Walsh &amp; Hoyt\u2019s Clinical Neuro-Ophthalmology, 5<\/em><em><sup>th<\/sup><\/em><em>\u00a0and 6<\/em><em><sup>th<\/sup><\/em><em>\u00a0Editions,<\/em>\u00a0and the popular manual\u00a0<em>Neuro-Ophthalmology Illustrated, 1<\/em><em><sup>st<\/sup><\/em><em>, 2<\/em><em><sup>nd<\/sup><\/em><em>\u00a0and 3<\/em><em><sup>rd<\/sup><\/em><em>\u00a0Editions<\/em>.\u00a0She has lectured widely throughout the world and is known for her innovative teaching style.\u00a0Her main research interests include disorders of the optic nerve and mitochondrial diseases.\u00a0She is a Trustee Emerita of the Board of Trustees of Princeton University and also served as President of the Princeton University Alumni Association.\n<ul>\n \t<li><strong>Sean Donahue, MD, PhD<\/strong><\/li>\n<\/ul>\nSean P. Donahue, MD, PhD is currently the Vice Chair for Clinical Affairs in the Department of Ophthalmology and Visual Sciences at Vanderbilt University Medical Center in Nashville, TN.\u00a0He attended College at the University of Dayton, followed by Medical and Graduate training at Emory University.\u00a0Dr. Donahue was fellowship trained in Pediatric Ophthalmology and Neuro-ophthalmology at the University of Iowa after completing his residency in Ophthalmology at the University of Pittsburgh.\u00a0\u00a0His primary clinical interests are in the diagnosis and management of pediatric ophthalmological problems, and in the surgical management of complicated strabismus syndromes.\u00a0\u00a0He is a member of the American Association for Pediatric Ophthalmology and Strabismus, the American Academy of Ophthalmology, the Heed Society, the Association for Research in Strabismus (Squint Club), and the American Ophthalmological Association (AOS).\u00a0He holds the inaugural Sam and Darthea Coleman Chair in Ophthalmology at Vanderbilt.\n\nDr. Donahue has served as the Program Chair for the American Association for Pediatric Ophthalmology and Strabismus, and on the Program Committee for the annual meetings of the North American Neuro Ophthalmology Society (NANOS) and the AOS.\u00a0\u00a0He has been on the Executive Committee, the Strabismus Steering Committee, and the Pediatric Optic Neuritis Study Planning Committee for the Pediatric Eye Disease Research Group.\u00a0He recently served as the Protocol Chair for the Intermittent Exotropia Surgery Study, which was the first NEI-sponsored multi-centered surgical study in pediatric ophthalmology in over 30 years.\u00a0\u00a0He is an Executive Editor of the American Journal of Ophthalmology, and has been on the editorial boards of the Journal of AAPOS, and the Journal of Clinical Neuro ophthalmology.\u00a0He has published over 300 peer-reviewed manuscripts, book chapters, and editorials, with over 100 as first author.\u00a0\u00a0He is widely sought-after as a guest lecturer and has spoken about clinical issues in pediatric ophthalmology on all six populated continents.\u00a0He is the past winner of the NANOS Young Investigator Award (2000), a Research to Prevent Blindness Career Development Award, and the Lifetime and Senior Achievement awards from AAO and AAPOS.\u00a0He was awarded the Distinguished Alumnus Award from the University of Dayton in 2015.\n","protected":false},"excerpt":{"rendered":"<ul>\n<li>Organis\u00e9e par GenSight Biologics (EPA: SIGHT)<\/li>\n<li>Jeudi 9 juillet<\/li>\n<li>10h00 (heure locale), 16h00 (Paris)<\/li>\n<\/ul>\n<p>Rejoindre le <a href=\"https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1332930&amp;tp_key=cef357cbf4\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>webcast<\/strong><\/a> en anglais<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[55],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[107],"class_list":["post-3543","post","type-post","status-publish","format-standard","hentry","category-evenements","post-year-107"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pr\u00e9sentation par des Leaders d&#039;Opinions du LUMEVOQ\u00ae pour le traitement de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL) | GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pr\u00e9sentation par des Leaders d&#039;Opinions du LUMEVOQ\u00ae pour le traitement de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL) | GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Organis\u00e9e par GenSight Biologics (EPA: SIGHT)  Jeudi 9 juillet  10h00 (heure locale), 16h00 (Paris) Rejoindre le webcast en anglais\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-24T19:52:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-04T03:35:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/06\\\/24\\\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/06\\\/24\\\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/4deb9538eb9b578965a0f75a4939ef0a\"},\"headline\":\"Pr\u00e9sentation par des Leaders d&rsquo;Opinions du LUMEVOQ\u00ae pour le traitement de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL)\",\"datePublished\":\"2020-06-24T19:52:38+00:00\",\"dateModified\":\"2026-11-04T03:35:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/06\\\/24\\\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\\\/\"},\"wordCount\":915,\"publisher\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\"},\"articleSection\":[\"\u00c9v\u00e9nements\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/06\\\/24\\\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/06\\\/24\\\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\\\/\",\"name\":\"Pr\u00e9sentation par des Leaders d'Opinions du LUMEVOQ\u00ae pour le traitement de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL) | GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-06-24T19:52:38+00:00\",\"dateModified\":\"2026-11-04T03:35:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/06\\\/24\\\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/06\\\/24\\\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/06\\\/24\\\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pr\u00e9sentation par des Leaders d&#8217;Opinions du LUMEVOQ\u00ae pour le traitement de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\",\"name\":\"GenSight Biologics\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Gensight-Logo-2.jpg\",\"contentUrl\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Gensight-Logo-2.jpg\",\"width\":696,\"height\":696,\"caption\":\"GenSight Biologics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/8104807?trk=prof-exp-company-name\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/4deb9538eb9b578965a0f75a4939ef0a\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pr\u00e9sentation par des Leaders d'Opinions du LUMEVOQ\u00ae pour le traitement de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL) | GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/","og_locale":"fr_FR","og_type":"article","og_title":"Pr\u00e9sentation par des Leaders d'Opinions du LUMEVOQ\u00ae pour le traitement de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL) | GenSight Biologics","og_description":"Organis\u00e9e par GenSight Biologics (EPA: SIGHT)  Jeudi 9 juillet  10h00 (heure locale), 16h00 (Paris) Rejoindre le webcast en anglais","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/","og_site_name":"GenSight Biologics","article_published_time":"2020-06-24T19:52:38+00:00","article_modified_time":"2026-11-04T03:35:11+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-1.jpg","type":"image\/jpeg"}],"author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/4deb9538eb9b578965a0f75a4939ef0a"},"headline":"Pr\u00e9sentation par des Leaders d&rsquo;Opinions du LUMEVOQ\u00ae pour le traitement de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL)","datePublished":"2020-06-24T19:52:38+00:00","dateModified":"2026-11-04T03:35:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/"},"wordCount":915,"publisher":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization"},"articleSection":["\u00c9v\u00e9nements"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/","name":"Pr\u00e9sentation par des Leaders d'Opinions du LUMEVOQ\u00ae pour le traitement de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL) | GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2020-06-24T19:52:38+00:00","dateModified":"2026-11-04T03:35:11+00:00","breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/06\/24\/presentation-par-des-leaders-dopinions-du-lumevoq-pour-le-traitement-de-la-nohl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Pr\u00e9sentation par des Leaders d&#8217;Opinions du LUMEVOQ\u00ae pour le traitement de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL)"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","publisher":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization","name":"GenSight Biologics","url":"https:\/\/www.gensight-biologics.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-2.jpg","contentUrl":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-2.jpg","width":696,"height":696,"caption":"GenSight Biologics"},"image":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/8104807?trk=prof-exp-company-name"]},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/4deb9538eb9b578965a0f75a4939ef0a","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3543"}],"version-history":[{"count":1,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3543\/revisions"}],"predecessor-version":[{"id":10424,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3543\/revisions\/10424"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3543"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3543"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3543"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3543"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}